Zacks: Analysts Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) to Post -$0.74 Earnings Per Share – Defense World

Posted by on May 10th, 2022
Brokerages forecast that TCR2 Therapeutics Inc. (NASDAQ:TCRRGet Rating) will report earnings per share of ($0.74) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for TCR2 Therapeutics’ earnings. The highest EPS estimate is ($0.68) and the lowest is ($0.79). TCR2 Therapeutics posted earnings per share of ($0.58) during the same quarter last year, which suggests a negative year over year growth rate of 27.6%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that TCR2 Therapeutics will report full year earnings of ($2.95) per share for the current year, with EPS estimates ranging from ($3.31) to ($2.60). For the next fiscal year, analysts forecast that the company will report earnings of ($2.66) per share, with EPS estimates ranging from ($4.30) to ($1.33). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow TCR2 Therapeutics.
TCR2 Therapeutics (NASDAQ:TCRRGet Rating) last released its quarterly earnings results on Tuesday, March 22nd. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.01.

TCRR has been the subject of a number of recent research reports. HC Wainwright dropped their price target on shares of TCR2 Therapeutics from $25.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, January 13th. Piper Sandler reduced their price target on shares of TCR2 Therapeutics from $26.00 to $23.00 in a report on Tuesday, March 22nd. The Goldman Sachs Group lowered shares of TCR2 Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $28.00 to $5.00 in a research report on Wednesday, January 19th. Finally, Zacks Investment Research lowered shares of TCR2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 18th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $17.39.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Moors & Cabot Inc. purchased a new position in TCR2 Therapeutics during the 3rd quarter worth $25,000. Macquarie Group Ltd. bought a new stake in TCR2 Therapeutics in the 3rd quarter valued at about $30,000. Newman Dignan & Sheerar Inc. purchased a new stake in TCR2 Therapeutics in the 1st quarter worth approximately $30,000. Private Advisor Group LLC bought a new stake in TCR2 Therapeutics during the fourth quarter valued at $52,000. Finally, Guggenheim Capital LLC bought a new stake in shares of TCR2 Therapeutics during the 4th quarter valued at about $53,000. 82.99% of the stock is owned by institutional investors and hedge funds.
Shares of TCR2 Therapeutics stock traded up $0.18 during trading on Tuesday, hitting $2.38. 28,128 shares of the company’s stock traded hands, compared to its average volume of 603,626. TCR2 Therapeutics has a twelve month low of $2.10 and a twelve month high of $20.44. The company has a market cap of $91.74 million, a PE ratio of -0.89 and a beta of 2.22. The firm’s fifty day moving average price is $2.55 and its 200 day moving average price is $3.91.
TCR2 Therapeutics Company Profile (Get Rating)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
See Also

Get a free copy of the Zacks research report on TCR2 Therapeutics (TCRR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Earnings History and Estimates for TCR2 Therapeutics (NASDAQ:TCRR)
Receive News & Ratings for TCR2 Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TCR2 Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
iSun, Inc. (NASDAQ:ISUN) Expected to Post Earnings of -$0.07 Per Share
Research Analysts’ Weekly Ratings Updates for Lennox International (LII)

Read More

source

Related posts

Leave a Reply

Your email address will not be published.